WuXi Biologics (Cayman) Inc
02269: XHKG (HKG)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
HK$35.80 | Dlttwy | Tzlbscdm |
WuXi Biologics: Project Addition Is a Key Indicator to Follow in the Upcoming Earnings
In WuXi Biologics’ upcoming earnings, we think the most important update to watch out for is project addition because we believe it reflects potential concerns over the acceptance of WuXi Bio by the global biotech and biopharma industry given the likely impending implementation of the Biosecure Act. Of note are the contract-developing projects in the early stages, potentially having at least 10 years to run until the end of commercial manufacturing.